Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide Extension in Acromegaly
NCT00171730Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Dec 2013
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in acromegaly, sponsored by Novartis. Primary endpoint: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response at Month 9. Started Aug 2004; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00171730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171730.